PhaseBio: SFJ Pharmaceuticals' Acquisition of Bentracimab Assets
Orrick advised SFJ Pharmaceuticals on the deal. SFJ Pharmaceuticals ("SFJ") announced its acquisition of assets related to Bentracimab, a drug with the potential to address a significant [...]
Read full article »
PhaseBio is a biopharmaceutical firm that researches and develops novel therapeutics for the treatment of orphan diseases.
Read more